FDA Clinical Decision Support: What AI Developers Must Know

In September 2022, the U.S. Food and Drug Administration (FDA) finalized its guidance on Clinical Decision Support (CDS) software, establishing a risk-based framework that clarifies which AI-driven tools fall under its regulatory oversight and which do not[1]. This guidance, rooted in the 21st Century Cures Act and further informed by years of industry feedback, is now the definitive reference for AI developers and healthcare executives seeking to balance innovation with compliance. The distinction between Device CDS—subject to FDA regulation—and Non-Device CDS—exempt from oversight—has immediate operational and strategic implications for any organization building or procuring AI-enabled clinical tools.

The FDA’s Risk-Based Approach: Device vs. Non-Device CDS

The FDA’s latest guidance is explicit: not all CDS software is regulated as a medical device. The agency applies a risk-based approach, consistent with its broader digital health strategy, to determine which software functions require oversight. According to the guidance, Non-Device CDS is exempt from FDA regulation if it meets four specific criteria: it is not intended to acquire, process, or analyze medical images or signals; it is intended to display, analyze, or print medical information; it supports or provides recommendations to healthcare professionals about prevention, diagnosis, or treatment; and it enables independent review of the basis for recommendations so that the healthcare professional can make the final decision[1]. This last criterion—often referred to as the “explainability” or “transparency” requirement—places a premium on AI systems that are interpretable and whose logic can be understood by clinicians.

Device CDS, by contrast, includes software functions that do not meet all four criteria. For example, if an AI tool processes raw ECG signals to detect arrhythmias and provides a diagnostic recommendation that is not independently reviewable by the clinician, it is classified as a medical device and subject to the FDA’s premarket review requirements. The risk-based framework aligns regulatory scrutiny with the potential impact of the software on patient health outcomes. High-risk tools—those that drive or replace clinical decision-making without clinician oversight—are regulated more stringently, while lower-risk, clinician-supportive tools are given regulatory leeway to foster innovation[1][2].

This distinction is not merely academic. For AI developers, it determines the scope of required documentation, the rigor of validation studies, and the timeline for bringing products to market. For healthcare organizations, it affects procurement decisions, risk management strategies, and the integration of AI tools into clinical workflows. The FDA’s approach is designed to prevent regulatory bottlenecks for low-risk innovations while ensuring that higher-risk tools are safe and effective before they reach patients.

Transparency, Explainability, and Clinician Involvement

A central tenet of the FDA’s guidance is that CDS software must enable independent review by the intended user—typically a healthcare professional. This requirement is especially salient for AI-driven CDS, where complex algorithms and machine learning models can create “black box” recommendations that are difficult to interpret. The FDA is explicit: if a clinician cannot independently assess the basis for an AI recommendation, the software does not qualify for exemption and is regulated as a device[1].

This has direct implications for AI developers. To qualify as Non-Device CDS, software must provide sufficient information about its logic, data inputs, and reasoning process so that clinicians can understand and evaluate the recommendations. This means that “explainable AI” is not just a best practice—it is a regulatory necessity. Developers must document the clinical evidence supporting their algorithms, describe the data sources and model limitations, and present recommendations in a format that is transparent and actionable for clinicians. The FDA’s guidance encourages the use of plain-language explanations, visualizations, and references to supporting literature to facilitate clinician understanding[1][2].

Clinician involvement is another key requirement. The software must be designed to support—not replace—clinical judgment. The FDA’s guidance draws a bright line between tools that assist clinicians in making decisions and those that automate or supplant clinical decision-making. AI developers must ensure that their CDS tools are positioned as aids to clinical workflow, with clear user interfaces that prompt review and validation by the healthcare professional. This not only supports regulatory compliance but also aligns with best practices in clinical governance and risk management.

Fostering Innovation: Clear Criteria and Reduced Barriers

The FDA’s updated guidance is widely recognized as a pro-innovation move, providing much-needed clarity for AI developers and healthcare organizations. By articulating clear criteria for Non-Device CDS, the agency has reduced regulatory uncertainty and lowered barriers to entry for AI-driven healthcare solutions. Developers can now design software functions with confidence, knowing which features will trigger FDA oversight and which will not[2].

This regulatory clarity has immediate practical benefits. AI startups and established vendors alike can accelerate development cycles by focusing on features that qualify for exemption, avoiding the time and expense of premarket submissions for low-risk tools. Healthcare organizations can more easily evaluate and adopt CDS software, knowing that exempt tools have been designed to support—not replace—clinician decision-making. The guidance also encourages innovation in explainability and user interface design, as developers compete to create AI tools that are both powerful and transparent.

However, the FDA’s approach is not a regulatory free-for-all. The agency reserves the right to intervene if exempt CDS tools are found to pose unforeseen risks to patient safety. Developers are expected to maintain robust documentation, conduct rigorous validation studies, and monitor real-world performance to ensure ongoing safety and effectiveness. The guidance also anticipates future advances in AI, signaling that the FDA will continue to update its framework as new technologies and clinical use cases emerge[1].

Post-Market Surveillance and Real-World Performance

While the FDA’s guidance provides a streamlined path to market for many AI-driven CDS tools, it also places a strong emphasis on post-market surveillance and real-world performance monitoring. This is especially critical for AI systems, which may evolve over time as they are exposed to new data and clinical environments. The FDA expects developers to implement processes for tracking software performance, collecting user feedback, and identifying potential safety issues after deployment[1].

For Device CDS, post-market requirements are well established: manufacturers must report adverse events, conduct periodic safety updates, and comply with quality system regulations. For Non-Device CDS, the expectations are less prescriptive but no less important. Developers should establish mechanisms for monitoring software behavior in the field, capturing real-world evidence of effectiveness, and updating algorithms as needed to address emerging risks. This may include automated logging of recommendations, clinician override rates, and patient outcomes, as well as structured processes for reviewing and responding to user-reported issues.

Healthcare organizations also have a role to play in post-market surveillance. CTOs and CISOs should work with vendors to ensure that CDS tools are integrated into clinical governance frameworks, with clear protocols for monitoring, reporting, and responding to safety signals. This includes establishing data-sharing agreements, defining roles and responsibilities for oversight, and ensuring that clinicians are trained to recognize and report potential issues. The FDA’s guidance underscores the importance of a continuous learning approach, where real-world data is used to refine and improve AI-driven CDS over time[1][2].

Operational Implications: What Healthcare Executives Must Do Now

For CTOs, CISOs, and compliance leaders in health systems, the FDA’s updated CDS guidance is both a roadmap and a call to action. In the next quarter, organizations should conduct a comprehensive inventory of all AI-driven CDS tools in use or under development, mapping each to the FDA’s risk-based framework. This includes reviewing software functions against the four exemption criteria, assessing the transparency and explainability of AI algorithms, and documenting clinician involvement in decision-making workflows.

Where Device CDS is identified, organizations must ensure that vendors have completed the necessary premarket submissions and that all required documentation is available for inspection. For Non-Device CDS, CTOs should verify that software provides clear, actionable explanations for recommendations and that clinicians are empowered to independently review and validate AI outputs. CISOs should work with compliance teams to establish robust post-market surveillance protocols, including real-world performance monitoring, adverse event reporting, and periodic safety reviews.

Procurement processes should be updated to require vendors to disclose the regulatory status of CDS tools, provide evidence of compliance with FDA guidance, and commit to ongoing monitoring and support. Training programs should be implemented to ensure that clinicians understand the capabilities and limitations of AI-driven CDS, and that they are equipped to exercise independent judgment in clinical decision-making.

Finally, executives should engage with industry groups, regulators, and technology partners to stay abreast of evolving FDA policies and best practices in AI governance. The FDA’s risk-based approach is designed to evolve alongside advances in AI technology, and proactive engagement will be critical to maintaining compliance and fostering innovation in clinical decision support.